Incorporating Human Relevant Stem-Cell Derived Cardiomyocytes in Drug Safety Studies: Inspirations and Future Aspirational Goals
Gary Gintant,
Research Fellow,
Abbvie
New applications for human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CM’s) continue to challenge users to define best uses for these cells and best practices for more comprehensive drug safety assessments. This presentation will discuss evolving uses for hiPSC-CMs involving inspirational cellular models and aspirational objectives in support of industrial in vitro cardiac safety screening and evaluations.
|
|
